Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

Author(s):
Lenos, K.; Grawenda, A.M.; Lodder, K.; Kuijjer, M.L.; Teunisse, A.F.A.S.; Repapi, E.; Grochola, L.F.; Bartel, F.; Hogendoorn, P.C.W.; Wuerl, P.; Taubert, H.; Cleton-Jansen, A.M.; Bond, G.L.; Jochemsen, A.G. (0000-0002-0570-7967)
Published
2012
Publication type
Article / Letter to editor
Date issued
2012-08-15
Language
English
Is part of
Cancer Research (2012), Vol. 72, no. 16, p. 4074-4084
hdl
1887/98132
doi
10.1158/0008-5472.CAN-12-0215